Amneal Pharmaceuticals, Inc. recently entered a long-term license agreement with Orion Corporation to commercialize various complex generic products, a press release reported. The financial terms of the deal were not disclosed.
“We are delighted to announce this collaboration with Amneal, and we look forward to working together to bring these treatments to patients,” Liisa Hurme, president and CEO of Orion, said. “This agreement expands our footprint in the European generics market as well as in Asia-Pacific region. In addition, it supports our growth strategy and is yet another fine example how Orion grows its business through high-quality strategic partnerships.”
Under the terms of the deal, Orion will serve as Amneal’s exclusive partner, and help expand its complex generic programs across Europe, as well as Australia and New Zealand.
The catalog will feature a wide range of generic products commercially available in the U.S., and a plan to develop additional high-value pipeline products.
“International expansion is a key strategic priority for Amneal and today’s announcement demonstrates our commitment to execute on that,” Chirag Patel and Chintu Patel, Amneal co-CEOs, said. “As a company, we are extremely focused on finding partners who share our same values, ethics and ambitions, and we truly could not have found a better European partner than Orion. We are excited to bring our medicines to the second largest global pharmaceutical market, and we hope that today is only the beginning of our work together.”